Targets — browse / sort / filter (view)
Data license: CC BY 4.0 · Data source: apt-scout automated curation pipeline (E. Dohi, NCNP) — values harvested from public databases; raw source stored per target
- id
- UniProt accession (human). Links to uniprot.org.
- gene_symbol
- Gene symbol (e.g. ITGB3).
- protein_name
- Protein name (UniProt).
- tier
- Tier 1 = PDB-anchored; Tier 1.5 = AlphaFold-confident.
- has_structure
- 1 if the target protein has a reported experimental 3D structure (PDB). This is the CORE requirement the aptamer-Kd layer is built around — filter to 1 for the structure-backed set.
- evidence_priority
- DETERMINISTIC, reproducible prioritisation (0-1) computed at build time from real harvested columns: 0.35*experimental-structure(PDB=1 / AlphaFold-only=0.3) + 0.30*Open-Targets-top-disease-score + 0.20*PREDICTED-surface-accessibility(A_surface=1) + 0.15*EV-detection(EV-Map). A transparent ranking AID, not a validation; the surface/EV terms are PREDICTIONS/DETECTIONS, not measured EV-surface exposure. Recomputable exactly from this DB.
- has_activation_state_pdb_pair
- 1 if a curated ACTIVE/INACTIVE PDB pair exists (only 11 targets).
- in_cev_map
- Detected in the EV-Map plasma-EV dataset (Rai & Greening 2025, Nat Cell Biol, 10.1038/s41556-025-01795-7) = 3,422 apt-scout targets (broad detected proteome). The EV-Map CONSERVED EV proteome is 182 proteins (42 non-EV); apt-scout matches 104 of these conserved EV-hallmark proteins as targets by gene (the other 78 are not apt-scout targets). Use the ev_hallmark_targets query for that subset. IMPORTANT: EV-Map detection means the protein is EV CARGO (present in the vesicle) — it does NOT mean surface-exposed. Rai & Greening 2025 run a separate membrane-impermeant biotinylation assay giving a 151-protein SURFACEOME, and show the conserved SDCBP/syntenin is luminal (not surface-accessible). For genuine EV-surface accessibility use that 151-protein set, not EV-Map presence.
- has_known_aptamer
- 1 if PubMed '(gene) AND (aptamer OR SELEX)' returned any hit (KEYWORD co-mention, includes false positives — NOT a verified aptamer). For verified aptamers with Kd, see the Binding-affinities (v_kd) layer.
- opentargets_top_disease_score
- Open Targets association score (0-1).
- aptamer_count_pubmed
- Number of PubMed hits for (this protein) AND (aptamer OR SELEX). Keyword co-occurrence — verify each (many co-mention without a real aptamer).
- aptamer_pmids
- The actual PubMed IDs behind the aptamer evidence — click each to read the paper. This is the source of the 'has aptamer' claim.
- surface_class
- PREDICTED membrane topology (HPA-derived, not a measurement): A_surface = integral/ecto cell-surface (predicted EV-surface accessible); A2_pm_peripheral = plasma-membrane cytoplasmic-leaflet (SRC/LYN/RHOA, predicted not reachable); A_assoc = secreted/corona; B_cargo = luminal cargo; unknown = no HPA localization. Lipid asymmetry can partially flip (PS via scramblase); confirm by protease-protection / intact-EV surface labelling. See v_surface_targets.
522 rows where has_cryoEM = 1, in_cev_map = 0 and tier = "Tier 1" sorted by evidence_priority descending
This data as json, CSV (advanced)
surface_class 5
- B_cargo 259
- A_surface 164
- A_assoc 45
- unknown 40
- A2_pm_peripheral 14
tier 1
- Tier 1 · 522 ✖
in_cev_map 1
- - · 522 ✖
has_structure 1
- 1 522
has_cryoEM 1
- 1 · 522 ✖
has_activation_state_pdb_pair 1
- 0 522
| id | gene_symbol | protein_name | tier | evidence_priority ▲ | has_structure | surface_class | pdb_count_total | alphafold_mean_pLDDT | has_cryoEM | has_activation_state_pdb_pair | activation_state_pdb_active | activation_state_pdb_inactive | has_known_aptamer | aptamer_count_pubmed | aptamer_pmids | in_cev_map | opentargets_top_disease_name | opentargets_top_disease_score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P13569 | CFTR | Cystic fibrosis transmembrane conductance regulator | Tier 1 | 0.824 | 1 | A_surface | 58 | 75.62 | 1 | 0 | 1 | 10 | 41148207, 31029337, 30595527, 22483890, 15657417 | 0 | cystic fibrosis | 0.9133535862571094 | ||
| Q14654 | KCNJ11 | ATP-sensitive inward rectifier potassium channel 11 | Tier 1 | 0.81 | 1 | A_surface | 9 | 83.81 | 1 | 0 | 0 | 0 | 0 | type 2 diabetes mellitus | 0.8651421397012851 | |||
| P07949 | RET | Proto-oncogene tyrosine-protein kinase receptor Ret | Tier 1 | 0.809 | 1 | A_surface | 34 | 78.81 | 1 | 0 | 1 | 83 | 41962371, 41744190, 41636718, 41526122, 41406741, 41171123, 41082837, 41060784, 41027166, 40932619, 40815127, 40711581, 40633058, 40602121, 40410423, 40285964, 40252505, 40222299, 39344894, 39288589, 39190775, 38953438, 38876068, 38852325, 38718747, 38604287, 38354543, 38282384, 38237282, 37851382, 37774402, 37757695, 37437453, 37245460, 36952259, 36315022, 35550937, 35420408, 34342436, 34132907, 34016094, 33513536, 33462661, 33119785, 33011620, 32760976, 32527800, 32212604, 32138930, 31897454 | 0 | medullary thyroid gland carcinoma | 0.8617460262224842 | ||
| Q12809 | KCNH2 | Voltage-gated inwardly rectifying potassium channel KCNH2 | Tier 1 | 0.806 | 1 | A_surface | 23 | 62.75 | 1 | 0 | 1 | 1 | 22617876 | 0 | Romano-Ward syndrome | 0.8549238933917284 | ||
| P82251 | SLC7A9 | b(0,+)-type amino acid transporter 1 | Tier 1 | 0.805 | 1 | A_surface | 4 | 85.44 | 1 | 0 | 0 | 0 | 0 | cystinuria | 0.8484952668941285 | |||
| Q695T7 | SLC6A19 | Sodium-dependent neutral amino acid transporter B(0)AT1 | Tier 1 | 0.804 | 1 | A_surface | 19 | 90.0 | 1 | 0 | 0 | 0 | 0 | Hartnup disease | 0.8464240093600148 | |||
| P41180 | CASR | Extracellular calcium-sensing receptor | Tier 1 | 0.804 | 1 | A_surface | 31 | 75.69 | 1 | 0 | 0 | 0 | 0 | familial hypocalciuric hypercalcemia 1 | 0.8460848589627423 | |||
| Q05586 | GRIN1 | Glutamate receptor ionotropic, NMDA 1 | Tier 1 | 0.803 | 1 | A_surface | 84 | 82.88 | 1 | 0 | 0 | 0 | 0 | neurodevelopmental disorder with or without hyperkinetic movements and seizures, autosomal dominant | 0.8446685494288694 | |||
| P07911 | UMOD | Uromodulin | Tier 1 | 0.803 | 1 | A_surface | 10 | 82.94 | 1 | 0 | 1 | 4 | 37533140, 35446786 | 0 | familial juvenile hyperuricemic nephropathy type 1 | 0.8446536377993564 | ||
| O43526 | KCNQ2 | Potassium voltage-gated channel subfamily KQT member 2 | Tier 1 | 0.803 | 1 | A_surface | 24 | 58.19 | 1 | 0 | 0 | 0 | 0 | Benign familial neonatal seizures | 0.8423358217314708 | |||
| Q9HBA0 | TRPV4 | Transient receptor potential cation channel subfamily V member 4 | Tier 1 | 0.801 | 1 | A_surface | 19 | 71.62 | 1 | 0 | 0 | 0 | 0 | metatropic dysplasia | 0.8356240344517467 | |||
| P16473 | TSHR | Thyrotropin receptor | Tier 1 | 0.8 | 1 | A_surface | 9 | 74.0 | 1 | 0 | 1 | 6 | 41054857, 40997970, 40588369, 38650837 | 0 | hypothyroidism due to TSH receptor mutations | 0.8327127196409464 | ||
| Q92736 | RYR2 | Ryanodine receptor 2 | Tier 1 | 0.8 | 1 | A_surface | 26 | 1 | 0 | 1 | 1 | 24130701 | 0 | catecholaminergic polymorphic ventricular tachycardia 1 | 0.8338648743498255 | |||
| Q8IZF0 | NALCN | Sodium leak channel NALCN | Tier 1 | 0.796 | 1 | A_surface | 5 | 76.69 | 1 | 0 | 0 | 0 | 0 | congenital contractures of the limbs and face, hypotonia, and developmental delay | 0.8198033442161259 | |||
| P41181 | AQP2 | Aquaporin-2 | Tier 1 | 0.795 | 1 | A_surface | 7 | 91.75 | 1 | 0 | 0 | 0 | 0 | diabetes insipidus, nephrogenic, autosomal | 0.817870726313342 | |||
| Q9ULV1 | FZD4 | Frizzled-4 | Tier 1 | 0.795 | 1 | A_surface | 11 | 84.31 | 1 | 0 | 1 | 1 | 18673242 | 0 | Familial exudative vitreoretinopathy | 0.8152111103672746 | ||
| Q13651 | IL10RA | Interleukin-10 receptor subunit alpha | Tier 1 | 0.795 | 1 | A_surface | 7 | 62.0 | 1 | 0 | 1 | 2 | 25870409, 25558474 | 0 | Autosomal recessive early-onset inflammatory bowel disease | 0.8151052076044897 | ||
| Q9H222 | ABCG5 | ATP-binding cassette sub-family G member 5 | Tier 1 | 0.793 | 1 | A_surface | 8 | 85.06 | 1 | 0 | 0 | 0 | 0 | sitosterolemia | 0.810555184820483 | |||
| Q9H1D0 | TRPV6 | Transient receptor potential cation channel subfamily V member 6 | Tier 1 | 0.789 | 1 | A_surface | 24 | 80.56 | 1 | 0 | 0 | 0 | 0 | hyperparathyroidism, transient neonatal | 0.7964821997780153 | |||
| Q14028 | CNGB1 | Cyclic nucleotide-gated channel beta-1 | Tier 1 | 0.788 | 1 | A_surface | 11 | 57.66 | 1 | 0 | 0 | 0 | 0 | retinitis pigmentosa | 0.7931901344765326 | |||
| P24530 | EDNRB | Endothelin receptor type B | Tier 1 | 0.786 | 1 | A_surface | 17 | 75.0 | 1 | 0 | 0 | 0 | 0 | Waardenburg syndrome type 4A | 0.7874601728728147 | |||
| Q03431 | PTH1R | Parathyroid hormone/parathyroid hormone-related peptide receptor | Tier 1 | 0.786 | 1 | A_surface | 52 | 70.94 | 1 | 0 | 0 | 0 | 0 | metaphyseal chondrodysplasia, Jansen type | 0.7859378587442476 | |||
| O60741 | HCN1 | Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 | Tier 1 | 0.786 | 1 | A_surface | 12 | 68.94 | 1 | 0 | 0 | 0 | 0 | Generalized epilepsy with febrile seizures-plus | 0.7853938745545654 | |||
| O43909 | EXTL3 | Exostosin-like 3 | Tier 1 | 0.785 | 1 | A_surface | 4 | 83.69 | 1 | 0 | 0 | 0 | 0 | immunoskeletal dysplasia with neurodevelopmental abnormalities | 0.7837827977649315 | |||
| P22888 | LHCGR | Lutropin-choriogonadotropic hormone receptor | Tier 1 | 0.785 | 1 | A_surface | 4 | 80.12 | 1 | 0 | 0 | 0 | 0 | Leydig cell hypoplasia, type 1 | 0.783461117057047 | |||
| P23416 | GLRA2 | Glycine receptor subunit alpha-2 | Tier 1 | 0.784 | 1 | A_surface | 13 | 83.81 | 1 | 0 | 0 | 0 | 0 | intellectual developmental disorder, X-linked, syndromic, Pilorge type | 0.7805605973560554 | |||
| P56696 | KCNQ4 | Potassium voltage-gated channel subfamily KQT member 4 | Tier 1 | 0.783 | 1 | A_surface | 13 | 65.25 | 1 | 0 | 0 | 0 | 0 | autosomal dominant nonsyndromic hearing loss 2A | 0.7765455627642878 | |||
| Q13224 | GRIN2B | Glutamate receptor ionotropic, NMDA 2B | Tier 1 | 0.783 | 1 | A_surface | 36 | 60.69 | 1 | 0 | 0 | 0 | 0 | intellectual disability, autosomal dominant 6 | 0.7771650025965382 | |||
| P30531 | SLC6A1 | Sodium- and chloride-dependent GABA transporter 1 | Tier 1 | 0.782 | 1 | A_surface | 5 | 87.94 | 1 | 0 | 0 | 0 | 0 | epilepsy with myoclonic atonic seizures | 0.7729414443362785 | |||
| Q9NY46 | SCN3A | Sodium channel protein type 3 subunit alpha | Tier 1 | 0.781 | 1 | A_surface | 2 | 68.25 | 1 | 0 | 0 | 0 | 0 | familial focal epilepsy with variable foci | 0.7708874082891223 | |||
| P43220 | GLP1R | Glucagon-like peptide 1 receptor | Tier 1 | 0.78 | 1 | A_surface | 70 | 81.5 | 1 | 0 | 1 | 2 | 40691365, 30957581 | 0 | type 2 diabetes mellitus | 0.7667004144705459 | ||
| Q07699 | SCN1B | Sodium channel regulatory subunit beta-1 | Tier 1 | 0.779 | 1 | A_surface | 36 | 87.06 | 1 | 0 | 0 | 0 | 0 | Generalized epilepsy with febrile seizures-plus | 0.7638796221342504 | |||
| Q01668 | CACNA1D | Voltage-dependent L-type calcium channel subunit alpha-1D | Tier 1 | 0.777 | 1 | A_surface | 6 | 64.31 | 1 | 0 | 0 | 0 | 0 | aldosterone-producing adenoma with seizures and neurological abnormalities | 0.7565859403082721 | |||
| P30518 | AVPR2 | Vasopressin V2 receptor | Tier 1 | 0.776 | 1 | A_surface | 38 | 76.0 | 1 | 0 | 0 | 0 | 0 | nephrogenic syndrome of inappropriate antidiuresis | 0.7522383646690638 | |||
| O15399 | GRIN2D | Glutamate receptor ionotropic, NMDA 2D | Tier 1 | 0.776 | 1 | A_surface | 13 | 63.22 | 1 | 0 | 0 | 0 | 0 | developmental and epileptic encephalopathy, 46 | 0.7529662497608808 | |||
| P48167 | GLRB | Glycine receptor subunit beta | Tier 1 | 0.775 | 1 | A_surface | 12 | 78.06 | 1 | 0 | 0 | 0 | 0 | hyperekplexia 2 | 0.7488854563756028 | |||
| P08588 | ADRB1 | Beta-1 adrenergic receptor | Tier 1 | 0.775 | 1 | A_surface | 7 | 75.31 | 1 | 0 | 0 | 0 | 0 | hypertension | 0.7498467911536156 | |||
| P04035 | HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Tier 1 | 0.774 | 1 | A_surface | 24 | 75.31 | 1 | 0 | 1 | 1 | 36470581 | 0 | Hypercholesterolemia | 0.7460937406970991 | ||
| P14416 | DRD2 | D(2) dopamine receptor | Tier 1 | 0.774 | 1 | A_surface | 11 | 72.44 | 1 | 0 | 0 | 0 | 0 | major depressive disorder | 0.7450892965426774 | |||
| P51681 | CCR5 | C-C chemokine receptor type 5 | Tier 1 | 0.773 | 1 | A_surface | 25 | 85.38 | 1 | 0 | 1 | 23 | 36576612, 33981364, 29678881, 29556342, 29301363, 27807347, 27652575, 26965267, 25794434, 25754473, 25329893, 23629001, 22811524, 21576818, 18799178, 16631118, 16227301, 15813986, 14610191, 12498773 | 0 | HIV infection | 0.7442590579227027 | ||
| P40259 | CD79B | B-cell antigen receptor complex-associated protein beta chain | Tier 1 | 0.773 | 1 | A_surface | 5 | 75.38 | 1 | 0 | 0 | 0 | 0 | diffuse large B-cell lymphoma | 0.7442791518522275 | |||
| P21860 | ERBB3 | Receptor tyrosine-protein kinase erbB-3 | Tier 1 | 0.77 | 1 | A_surface | 23 | 72.44 | 1 | 0 | 1 | 9 | 40851486, 33770580, 33039492, 31846731, 31626948, 29440899, 23990977, 22733765, 18942860 | 0 | visceral neuropathy, familial, 1, autosomal recessive | 0.7335342096528644 | ||
| Q8NET8 | TRPV3 | Transient receptor potential cation channel subfamily V member 3 | Tier 1 | 0.769 | 1 | A_surface | 34 | 76.5 | 1 | 0 | 0 | 0 | 0 | Olmsted syndrome 1 | 0.7314859339994324 | |||
| Q9NPC2 | KCNK9 | Potassium channel subfamily K member 9 | Tier 1 | 0.769 | 1 | A_surface | 22 | 75.94 | 1 | 0 | 0 | 0 | 0 | Birk-Barel syndrome | 0.73064701208734 | |||
| P47871 | GCGR | Glucagon receptor | Tier 1 | 0.766 | 1 | A_surface | 27 | 81.88 | 1 | 0 | 1 | 5 | 28775305, 23770039, 23744070 | 0 | GCGR-related hyperglucagonemia | 0.7213152740071143 | ||
| P28223 | HTR2A | 5-hydroxytryptamine receptor 2A | Tier 1 | 0.761 | 1 | A_surface | 38 | 73.75 | 1 | 0 | 0 | 0 | 0 | major depressive disorder | 0.703395899986692 | |||
| P40225 | THPO | Thrombopoietin | Tier 1 | 0.761 | 1 | A_surface | 3 | 61.44 | 1 | 0 | 1 | 2 | 38928037, 30312735 | 0 | thrombocythemia 1 | 0.7027329039559379 | ||
| Q9BYF1 | ACE2 | Angiotensin-converting enzyme 2 | Tier 1 | 0.758 | 1 | A_surface | 100 | 90.69 | 1 | 0 | 1 | 91 | 41716474, 41541792, 41274248, 40642289, 40333723, 40321580, 40227272, 39964138, 39923730, 39281706, 38973558, 38553521, 37932762, 37808754, 37692001, 37666993, 37385465, 37375202, 36950312, 36822303, 36714461, 36683236, 36581924, 36073793, 35972202, 35910791, 35907639, 35542182, 34876524, 34855379, 34847324, 34798263, 34696413, 34619249, 34458322, 34282416, 34248841, 34230708, 34230707, 34166652, 34123223, 33684258, 33683787, 33629859, 33561300, 33389440, 32981365, 32838280, 32551560, 36288301, 36170362, 35748608, 34953639 | 0 | COVID-19 | 0.6925739512122528 | ||
| Q14973 | SLC10A1 | Hepatic sodium/bile acid cotransporter | Tier 1 | 0.758 | 1 | A_surface | 11 | 83.5 | 1 | 0 | 0 | 0 | 0 | hypercholanemia, familial, 2 | 0.6937781800382379 | |||
| P48546 | GIPR | Gastric inhibitory polypeptide receptor | Tier 1 | 0.758 | 1 | A_surface | 13 | 78.5 | 1 | 0 | 0 | 0 | 0 | obesity | 0.6926187130965883 |
Advanced export
JSON shape: default, array, newline-delimited
CREATE VIEW v_targets AS
SELECT f.id, n.gene_symbol, n.protein_name, tg.tier,
-- evidence_priority: DETERMINISTIC, reproducible from real DB columns (no LLM).
-- Transparent weights over harvested evidence: structure 0.35, disease importance
-- 0.30 (Open Targets top-disease score), PREDICTED surface accessibility 0.20,
-- EV detection 0.15. A heuristic ranking aid, not a validation; surface/EV terms
-- are predictions/detections, NOT measured EV-surface exposure.
ROUND(
0.35*(CASE WHEN CAST(COALESCE(f.pdb_count_total,'0') AS INTEGER)>0 THEN 1.0
WHEN CAST(COALESCE(NULLIF(f.alphafold_mean_pLDDT,''),'0') AS REAL)>0 THEN 0.3 ELSE 0.0 END)
+ 0.30*MIN(CAST(COALESCE(NULLIF(f.opentargets_top_disease_score,''),'0') AS REAL), 1.0)
+ 0.20*(CASE sc.surface_class WHEN 'A_surface' THEN 1.0 WHEN 'A_assoc' THEN 0.5 WHEN 'A2_pm_peripheral' THEN 0.2 ELSE 0.0 END)
+ 0.15*(CASE WHEN CAST(COALESCE(f.in_cev_map,0) AS INTEGER)=1 THEN 1.0 ELSE 0.0 END)
, 3) AS evidence_priority,
(CASE WHEN CAST(COALESCE(f.pdb_count_total,'0') AS INTEGER)>0 THEN 1 ELSE 0 END) AS has_structure,
sc.surface_class,
f.pdb_count_total, f.alphafold_mean_pLDDT, f.has_cryoEM,
f.has_activation_state_pdb_pair, f.activation_state_pdb_active, f.activation_state_pdb_inactive,
f.has_known_aptamer, f.aptamer_count_pubmed, ap.aptamer_pmids,
f.in_cev_map, f.opentargets_top_disease_name, f.opentargets_top_disease_score
FROM v_target_full f
LEFT JOIN target_names n ON n.target_id=f.id
LEFT JOIN targets tg ON tg.id=f.id
LEFT JOIN target_aptamer_pmids ap ON ap.target_id=f.id
LEFT JOIN membrane_surface_class sc ON sc.target_id=f.id;